First Efficacy Study for Janssen's Mosaic HIV-1 Preventive Vaccine Starting
Proof-of-concept trialing will soon begin for Janssen's promising HIV-1 prophylactic vaccine, with backing from the Gates Foundation and the NIH.
You may also be interested in...
ViiV and Merck are looking to novel mechanisms of action as an opportunity to make up ground on HIV leader Gilead, which has de-emphasized early virology research.
Evotec’s multimodality approach to drug discovery landed the biotech two new discovery collaborations this week, underscoring its emphasis on patient-driven data.
Novo Nordisk and Evotec will identify and develop novel drugs for treating chronic kidney disease, using datasets of CKD patients provided by the Danish group and from other sources.